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Introduction
Oncolytic viruses are gaining acceptance as a method of
tumor immunotherapy, and some studies have reported
improved anti-tumor T cell responses after acute pyretic
non-oncolytic infections. Therefore, we hypothesized that
viral infections may aid in the immunotherapy of cancer.
Methods
To test this hypothesis, we used the A/H1N1/PR8
mouse model of influenza infection (10,000 pfu, via
intranasal administration) prior to or after challenge
with B16 melanoma (12,000 - 120,000 cells via intrader-
mal injection in the right flank). Kaplan-Meier curves
were used to present animal survival and tumor inci-
dence data and log rank test was used to compare such
curves. All statistical analyses were performed using
Prism software (v4.0, GraphPad software), and a p value
of less than 0.05 was considered to denote statistically
significant differences among compared variables.
Results
Contrary to our hypothesis, we observed that acute
influenza infection of the lung promotes distant mela-
noma growth in the dermis of the flank and results in
up to 50% decrease in host survival (P < 0.001). We
observed similar findings across a series of different
infection and tumor models. In experiments designed to
determine whether infection could lead to the emer-
gence of cancer that is otherwise controlled by the
immune system, we challenged mice with serial cell
numbers of B16 (12,000 and 1,200) at which tumor inci-
dence is reduced (to 60% and 0%, respectively). Here,
influenza infection significantly increased tumor inci-
dence for both 12,000 and 1,200 B16 cell challenges to
100% (P < 0.01 and P < 0.001, respectively). Further,
using a tumor transplant model we demonstrated that
anti-melanoma CD8+ T cells (defined by a congenic
marker and/or tetramer) in the context of influenza
infection are shunted to the lungs (P < 0.01 vs non-
infected mice), where they express high levels of the
activation and exhaustion receptor, PD-1 (P < 0.01).
Immunotherapy with PD-1 blockade reverses this loss of
anti-tumor CD8+ T cells from the tumor and decreases
viral infection-induced tumor growth.
Conclusions
Our findings define a previously unrecognized mechan-
ism of immune suppression in cancer-bearing hosts,
namely acute non-oncogenic viral infection. This finding
may be important because it raises concerns over
patient exposure to acute viral illness, vaccination, and
treatment with viral vectors in tumor immunotherapy;
and it highlights an unexpected mechanism of PD-1
blockade in the treatment of cancer.
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